Perrigo Completes $1.5bn Rx Divestment
New Owner Altaris Capital Rebrands Prescription Unit As Padagis
Executive Summary
Perrigo has completed the divestment of its Rx prescription generics business to Altaris Capital Partners for $1.55bn, completing its transition to become a self-care consumer healthcare-focused company. Altaris has rebranded the unit as Padagis.
You may also be interested in...
The Generics Bulletin Top 50, Part One: Indian Leaders Climb Into Top 10
In a year that has seen significant changes throughout our generics and biosimilars industry ranking, the top 10 has welcomed two Indian off-patent leaders after two other firms dropped out of the top table. We delve into what has changed in the first instalment of this year’s Generics Bulletin Top 50.
Padagis Achieves A US First With Budesonide Foam Launch
Padagis has launched budesonide 2mg rectal foam, the first US generic version of Uceris, with 180 days of competitive generic therapy exclusivity.
Padagis Introduces Fresh Narcan Rival In US
Padagis has added fresh competition on Narcan in the US, with its nasal naloxone spray introduced to the market as part of a trio of launches that also includes adapalene gel and betamethasone ointment.